Neurogenic dry eye associated with intravitreal injection of anti-VEGF agents
CONCLUSIONS: Patients with a history of intraocular lens implantation, Nd:YAG laser posterior capsulotomy, and femtosecond laser-assisted laser in situ keratomileusis surgery may have increased drug permeability due to an increased concentration of anti-VEGF drugs in the aqueous layer and thinning of the stromal layer of the cornea. The corneal subepithelial nerve repair mechanism was destroyed, causing neurogenic dry eye.PMID:37350417 | DOI:10.1177/11206721231177475 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 23, 2023 Category: Opthalmology Authors: Shu-Hua Lin Yu-Hui Fang Fa-Li Jia Ying-Jun Li Source Type: research
Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial
Conclusion
EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy.
Trial registration number
NCT01006538. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - June 22, 2023 Category: Opthalmology Authors: Jackson, T. L., Soare, C., Petrarca, C., Simpson, A., Neffendorf, J. E., Petrarca, R., Muldrew, K. A., Peto, T., Chakravarthy, U., Membrey, L., Haynes, R., Costen, M., Steel, D. H. W., Desai, R., for the MERLOT Study Group, Bishop, Doyle, Elghrably, Gupta Tags: Editor's choice Original articles - Clinical science Source Type: research
Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials
Conclusions
In this exploratory analysis, patients with diabetes taking thiazolidinediones and treated with bevacizumab or ranibizumab for nAMD had worse baseline mean VA, greater reductions in subretinal and subretinal tissue complex thickness from baseline, and greater proportions with IRF comparing to patients not taking thiazolidinediones.
Trial registration number
ClinicalTrials.gov NCT00593450. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - June 22, 2023 Category: Opthalmology Authors: Core, J. Q., Hua, P., Daniel, E., Grunwald, J. E., Jaffe, G., Maguire, M. G., Ying, G.-s., for the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Williams, Beardsley, Bennett, Cantrill, Chan-Tram, Cheshier, Davies, Tags: Original articles - Clinical science Source Type: research
Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab
ConclusionEyes treated with bevacizumab and ranibizumab can achieve similar anatomical and functional improvement. CNV recurrence may occur earlier and more frequently during the first year in eyes treated with ranibizumab. (Source: International Ophthalmology)
Source: International Ophthalmology - June 15, 2023 Category: Opthalmology Source Type: research
Population Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Implanted in the Eye in Patients With Neovascular Age-Related Macular Degeneration
This article is protected by copyright. All rights reserved.PMID:37291950 | DOI:10.1002/jcph.2290 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 9, 2023 Category: Drugs & Pharmacology Authors: Matts K ågedal Oskar Alsk är Klas Petersson Eva Hanze Mauricio Maia Tong Lu Shweta Vakhavkar Angelica Quartino Jeffrey R Willis Jin Y Jin Katie F Maass Source Type: research
Population Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Implanted in the Eye in Patients With Neovascular Age-Related Macular Degeneration
This article is protected by copyright. All rights reserved.PMID:37291950 | DOI:10.1002/jcph.2290 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 9, 2023 Category: Drugs & Pharmacology Authors: Matts K ågedal Oskar Alsk är Klas Petersson Eva Hanze Mauricio Maia Tong Lu Shweta Vakhavkar Angelica Quartino Jeffrey R Willis Jin Y Jin Katie F Maass Source Type: research
Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases
Eur J Med Chem. 2023 May 29;257:115535. doi: 10.1016/j.ejmech.2023.115535. Online ahead of print.ABSTRACTAngiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular endothelial growth factor receptor (VEGFR) is a crucial cell membrane receptor that binds to VEGF to regulate angiogenesis and maintenance. Dysregulation of VEGFR signaling can lead to several diseases, such as cancer and ocular neovascular disease, making it a crucial research area for disease treatment. Currently, anti-VE...
Source: European Journal of Medicinal Chemistry - June 7, 2023 Category: Chemistry Authors: Die Jiang Ting Xu Lei Zhong Qi Liang Yonghe Hu Wenjing Xiao Jianyou Shi Source Type: research
Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases
Eur J Med Chem. 2023 May 29;257:115535. doi: 10.1016/j.ejmech.2023.115535. Online ahead of print.ABSTRACTAngiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular endothelial growth factor receptor (VEGFR) is a crucial cell membrane receptor that binds to VEGF to regulate angiogenesis and maintenance. Dysregulation of VEGFR signaling can lead to several diseases, such as cancer and ocular neovascular disease, making it a crucial research area for disease treatment. Currently, anti-VE...
Source: European Journal of Medicinal Chemistry - June 7, 2023 Category: Chemistry Authors: Die Jiang Ting Xu Lei Zhong Qi Liang Yonghe Hu Wenjing Xiao Jianyou Shi Source Type: research
CO35 Real-World Effectiveness of Intravitreal Ranibizumab and Aflibercept for Eyes with Central Retinal Vein Occlusion: A Multi-Institutional Cohort Study in Taiwan
Intravitreal ranibizumab and aflibercept is the mainstream therapy for central retinal vein occlusion (CRVO), a common cause of vision loss in adults. However, the long-term effectiveness of changes in central retinal thickness (CRT) and visual acuity (VA) post ranibizumab and aflibercept therapy remains unclear in Taiwan. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: C. Liu, S.C. Shao Source Type: research
EE313 Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar
This study aims to calculate savings generated from the switch of the reference ranibizumab molecule, to a ranibizumab biosimilar, and explore how savings could be reinvested. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, I. Rickard, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research
EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar
This examined the impact of differing ophthalmology biosimilar switching policies on cost-savings for Canadian payors. The anticipated budget impact of a ranibizumab biosimilar was estimated across ten provincial drug plans. Resulting analysis identified possible opportunities for increased drug plan cost-savings associated with adopting proactive biosimilar switching policies. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, N. Goyert-Stephens, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research
Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis
CONCLUSION: This study found that there was no difference in BCVA, CMT or adverse reactions between AFL and RAN at 6 and 12 months of follow-up, but AFL needed fewer IVIs than RAN.PMID:37226427 | DOI:10.1177/11206721231178658 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - May 25, 2023 Category: Opthalmology Authors: Haiyan Chen Xuehui Shi Wang Zhang Qianqian Han Source Type: research
Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis
ConclusionConbercept had a higher rate of primary cure in ROP patients. More RCTs are needed to compare the efficacy of conbercept and ranibizumab in treating ROP. (Source: International Journal of Clinical Pharmacy)
Source: International Journal of Clinical Pharmacy - May 19, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
ConclusionBrolucizumab 6 mg Q12W/Q8W was comparable or superior to aflibercept 2 mg and ranibizumab 0.5 mg regimens for various visual and anatomical efficacy outcomes and discontinuation rates. (Source: Diabetes Therapy)
Source: Diabetes Therapy - May 17, 2023 Category: Endocrinology Source Type: research
